title: [Cognitive disorders and their correction in patients with ischemic stroke].
abstract: A study of the effectiveness of long-term (within a year) use cytoprotector neuropeptide nature of the drug cortexin (in the acute, early and late recovery periods) on the dynamics of the cognitive status of patients with ischemic stroke. The study involved 80 patients first ischemic stroke (IS). The patients of the main group (40 patients) received standard therapy cortexin + 10 mg once a day intramuscularly for 10 days with the same course again at 3, 6, 9 months during the year, the control group (40 people) - basic and vascular therapy for year. Four-time reception cortexin for a year at 10 mg once a day for 10 days promotes regression pronounced movement disorders, stabilize and restore cognitive function, and minimize the likelihood of post-stroke cognitive impairment during the recovery period.
authors.forename: M A
authors.initials: MA
authors.lastname: Evzel'man
authors.forename: N A
authors.initials: NA
authors.lastname: Aleksandrova
mesh_terms: D000328:Adult; D000368:Aged; D002545:Brain Ischemia / Q000150:complications* / Q000503:physiopathology; D003071:Cognition / Q000502:physiology*; D003072:Cognition Disorders / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D004305:Dose-Response Relationship, Drug; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007273:Injections, Intramuscular; D036341:Intercellular Signaling Peptides and Proteins; D008297:Male; D008875:Middle Aged; D010455:Peptides / Q000008:administration & dosage*; D020127:Recovery of Function; D016896:Treatment Outcome
chemical_list: D036341:Intercellular Signaling Peptides and Proteins; D010455:Peptides; C056590:cortexin